Physician profile
Moon Mock Oh
NPI 1902838881
$8,733.08
in general payments reported to CMS, 2019-2025
25 companies · $888 in 2025
The $888 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,782 · 2020: $673 · 2021: $1,207 · 2022: $1,661 · 2023: $467 · 2024: $1,055 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,038.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,313.19 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $683.91 | 2019-2022 | |
| Lilly USA, LLC | $535.31 | 2019-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $390.20 | 2019-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $325.24 | 2021-2024 | |
| Amgen INC. | $261.49 | 2019-2022 | |
| Esperion Therapeutics, INC. | $231.71 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.04 | 2019-2022 | |
| Pfizer INC. | $200.70 | 2019-2021 | |
| Exact Sciences Corporation | $198.79 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $186.40 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.82 | 2022 | |
| Abbvie INC. | $165.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $159.64 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $154.22 | 2020-2024 | |
| Eisai INC. | $120.35 | 2024 | |
| Sanofi-Aventis U.S. LLC | $106.40 | 2019-2022 | |
| Astellas Pharma US INC | $105.43 | 2023 | Veozah |
| Radius Health, INC. | $69.31 | 2019-2020 | |
| Vivus LLC | $24.19 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.13 | 2020 | |
| Sumitomo Pharma America, INC. | $16.62 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.97 | 2022 | |
| Biogen, INC. | $14.57 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moon Mock Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.